An update on the development on tubulin inhibitors for the treatment of solid tumors.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 101127833 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7631 (Electronic) Linking ISSN: 14728222 NLM ISO Abbreviation: Expert Opin Ther Targets Subsets: MEDLINE
    • Publication Information:
      Publication: London : Informa Healthcare
      Original Publication: London : Ashley Publications, c2001-
    • Subject Terms:
      Neoplasms*/drug therapy ; Neoplasms*/pathology ; Drug Development* ; Tubulin Modulators*/pharmacology ; Antineoplastic Agents*/pharmacology ; Microtubules*/drug effects ; Microtubules*/metabolism ; Molecular Targeted Therapy*; Humans ; Animals ; Drug Design ; Biological Products/pharmacology ; Tubulin/metabolism
    • Abstract:
      Introduction: Microtubules play a vital role in cancer therapeutics. They are implicated in tumorigenesis, thus inhibiting tubulin polymerization in cancer cells, and have now become a significant target for anticancer drug development. A plethora of drug molecules has been crafted to influence microtubule dynamics and presently, numerous tubulin inhibitors are being investigated. This review discusses the recently developed inhibitors including natural products, and also examines the preclinical and clinical data of some potential molecules.
      Area Covered: The current review article summarizes the development of tubulin inhibitors while detailing their specific binding sites. It also discusses the newly designed inhibitors that may be useful in the treatment of solid tumors.
      Expert Opinion: Microtubules play a crucial role in cellular processes, especially in cancer therapy where inhibiting tubulin polymerization holds promise. Ongoing trials signify a commitment to revolutionizing cancer treatment and exploring targeted therapies. Challenges in microtubule modulation, like resistance and off-target effects, demand focused efforts, emphasizing combination therapies and personalized treatments. Beyond microtubules, promising avenues in cancer research include immunotherapy, genomic medicine, CRISPR gene editing, liquid biopsies, AI diagnostics, and stem cell therapy, showcasing a holistic approach for future advancements.
    • Contributed Indexing:
      Keywords: Anti-cancer; cancer treatment; drug discovery; microtubules; tubulin polymerization inhibitors
    • Accession Number:
      0 (Tubulin Modulators)
      0 (Antineoplastic Agents)
      0 (Biological Products)
      0 (Tubulin)
    • Publication Date:
      Date Created: 20240415 Date Completed: 20240522 Latest Revision: 20240522
    • Publication Date:
      20240523
    • Accession Number:
      10.1080/14728222.2024.2341630
    • Accession Number:
      38618889